G. CLEVES: Open Payments
NPI 1023086386 · CINCINNATI, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,398 in 63 payments from 23 companies in 2025. Trend: 2023 $1,375 · 2024 $1,667 · 2025 $1,398
Food & beverage: $1,398
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $207 |
| ABBVIE INC. | 9 | $174 |
| Novo Nordisk Inc | 7 | $142 |
| Eisai Inc. | 5 | $108 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $78 |
| Gilead Sciences, Inc. | 3 | $75 |
| Exact Sciences Corporation | 4 | $69 |
| Astellas Pharma US Inc | 3 | $66 |
| Lilly USA, LLC | 3 | $57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $49 |
Products named: FARXIGA, Leqembi, UBRELVY, XIFAXAN, Veozah, QULIPTA, MOUNJARO, Wegovy.
Industry payments across OH — which companies pay providers there.
